Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: A retrospective study

Shiping Jiao, Wenjie Liu, Minqing Wu, Cheng Peng, Hailin Tang, Xiaoming Xie

    Research output: Contribution to journalArticle

    2 Scopus citations

    Abstract

    BACKGROUND: Existing reports showed loss of Nrdp1, an E3 ubiquitin ligase, promoted breast cancer malignancy because of failure to deregulate ErbB3. However, the correlation between Nrdp1 expression with clinical data is still unknown. OBJECTIVE: We explored the predictive value of Nrdp1 regarding the clinical outcome of patients and the benefit of adjuvant anthracycline-based chemotherapy. METHODS: 113 primary breast cancer samples were obtained during surgery and the patients received average 10-year follow-up. We obtained Nrdp1 and ErbB3 expressions by immunohistochemstry. RESULTS: Nrdp1 expression correlates with overall survival and disease-free survival of patients, with a hazard ratio of 0.237 (p=0.001) and 0.280 (p < 0.001) respectively. Additionally Nrdp1 correlates inversely with ErbB3 expression in tumor tissue (p=0.009). However the prognosis of Nrdp1 was not solely dependent on its regulation of ErbB3 degradation since there was also a significant correlation between Nrdp1 and overall survival (p=0.005) in ErbB3-negative patients. In patients who received anthracycline-based chemotherapy, low Nrdp1 expression indicated decreased disease-free survival (p=0.006) and high rates of metastasis and/or recurrence (p <0.001). CONCLUSION: Nrdp1 may serve as a useful biomarker for the clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer.The prognosis of Nrdp1 was not solely dependent on its deregulation of ErbB3.

    Original languageEnglish (US)
    Pages (from-to)115-123
    Number of pages9
    JournalCancer Biomarkers
    Volume15
    Issue number2
    DOIs
    StatePublished - Jan 1 2015

    Keywords

    • ErbB3
    • Nrdp1
    • anthracyclines-based chemotherapy
    • biomarker
    • breast cancer
    • prognosis

    ASJC Scopus subject areas

    • Oncology
    • Genetics
    • Cancer Research

    Fingerprint Dive into the research topics of 'Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: A retrospective study'. Together they form a unique fingerprint.

  • Cite this